Court Finds Bayer’s Yasmin Oral Contraceptive Patent Is Invalid
This article was originally published in The Pink Sheet Daily
Executive Summary
A district court ruling against Bayer’s oral contraceptive patent opens the way for Barr to launch a generic version of Yasmin.